Recent XRAY stock performance
On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share. The stock declined by ~0.14% on the day. XRAY stock was trading at a 52-week high of $68.98 on November 28, 2017. However, the company’s 52-week low came on April 2, 2018, at $48.25. This recent stock price decline was triggered by negative investor sentiments for the company due to recent target price cuts by Wall Street analysts following downward revisions and modelling adjustments in the company’s fiscal 4Q17 earnings release on March 2 and the recent OraMetrix acquisition announcement.
After the formation of Dentsply Sirona with the merger of Dentsply International and Sirona Dental Systems in February 2016, the company has struggled with integration challenges. Despite a market-leading product portfolio, the company has seen some challenging times over the last few years. Its stock prices have been volatile over the last few quarters with significant price movements following the quarterly earnings releases. On March 5, 2018, XRAY stock fell ~3.1% after several analysts reduced their 12-month target prices on Dentsply Sirona stock. The company recorded ~$2.0 billion of non-cash impairment charges in fiscal 2017 due to the lower-than-expected synergies the company recorded from the integration of Dentsply International and Sirona Dental Systems in February 2016. In January 2018, the company appointed a new CEO, which triggered a stock price decline of ~4.8% on January 17, 2018. For more on management changes, read Will These Management Changes Drive Dentsply Sirona toward a New Growth Trajectory?
Year-to-date, XRAY stock has declined ~27%. Over the past one month, the stock has registered a fall of ~15%, and the stock has fallen ~25% over the last three months. Currently, Dentsply Sirona is trading lower than its 50-day moving average of $54.76 per share as well as its 200-day moving average of $60.81.
Over the past one year, XRAY stock has fallen ~20%. In comparison, the S&P 500 Index (SPY), which reflects the performance of the broader market, registered returns of ~13% during the last one year. The US medical device sector (IHI) rose ~23.4% during the same period.
As of April 9, 2018, peers Zimmer Biomet Holdings (ZBH), Integra LifeSciences (IART), and Align Technology (ALGN) registered share price returns of -9.4%, 35.5%, and 122%, respectively, over the last 12 months.